These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31875623)

  • 1. Discovery of IL-6 and Development of Anti-IL-6R Antibody.
    Kishimoto T
    Keio J Med; 2019; 68(4):96. PubMed ID: 31875623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab (Actemra).
    Sheppard M; Laskou F; Stapleton PP; Hadavi S; Dasgupta B
    Hum Vaccin Immunother; 2017 Sep; 13(9):1972-1988. PubMed ID: 28841363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anti-interleukin-6 receptor antibody therapy--from bedside to bench].
    Nishimoto N
    Nihon Rinsho Meneki Gakkai Kaishi; 2006 Oct; 29(5):289-94. PubMed ID: 17075187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapeutic implication of IL-6 blockade.
    Tanaka T; Kishimoto T
    Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.
    Nishimoto N; Terao K; Mima T; Nakahara H; Takagi N; Kakehi T
    Blood; 2008 Nov; 112(10):3959-64. PubMed ID: 18784373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-6 as a key player in systemic inflammation and joint destruction.
    Fonseca JE; Santos MJ; Canhão H; Choy E
    Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases.
    Alten R; Maleitzke T
    Ann Med; 2013 Jun; 45(4):357-63. PubMed ID: 23650978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
    Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
    Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role and therapeutic targeting of IL-6 in rheumatoid arthritis.
    Narazaki M; Tanaka T; Kishimoto T
    Expert Rev Clin Immunol; 2017 Jun; 13(6):535-551. PubMed ID: 28494214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases.
    Ding C; Jones G
    Rev Recent Clin Trials; 2006 Sep; 1(3):193-200. PubMed ID: 18473972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.
    Nakahara H; Nishimoto N
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):373-81. PubMed ID: 17214583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective.
    Murakami M; Nishimoto N
    Curr Opin Rheumatol; 2011 May; 23(3):273-7. PubMed ID: 21427577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humanized antihuman IL-6 receptor antibody, tocilizumab.
    Nishimoto N; Kishimoto T
    Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic uses of anti-interleukin-6 receptor antibody.
    Kang S; Tanaka T; Kishimoto T
    Int Immunol; 2015 Jan; 27(1):21-9. PubMed ID: 25142313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunotherapy using IL-6 receptor as the target].
    Nishimoto N
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):399-404. PubMed ID: 18974624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical value of blocking IL-6 receptor.
    Mima T; Nishimoto N
    Curr Opin Rheumatol; 2009 May; 21(3):224-30. PubMed ID: 19365268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease].
    Ohsugi Y; Tsuchimoto N
    Nihon Yakurigaku Zasshi; 2005 Dec; 126(6):419-25. PubMed ID: 16462093
    [No Abstract]   [Full Text] [Related]  

  • 18. The blockade of IL-6 signaling in rational drug design.
    Adachi Y; Yoshio-Hoshino N; Nishimoto N
    Curr Pharm Des; 2008; 14(12):1217-24. PubMed ID: 18473869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic targeting of the interleukin-6 receptor.
    Tanaka T; Narazaki M; Kishimoto T
    Annu Rev Pharmacol Toxicol; 2012; 52():199-219. PubMed ID: 21910626
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.